Monographie - Infliximab - Stabilis 4.0

Last update :
19/11/2024

Immunosuppressant

Infliximab

injection

Eye-drops

Stability in solutions

Stability of mixtures

Factors which affect stability

Compatibility

Route of administration

References

pdf

Tradename

Tradename

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Flixabi	Belgium, Germany, Great Britain, Spain
Flixceli	Peru
Inflectra	Belgium, Canada, Germany, Great Britain, Iceland, Italy, Romania, Spain, Switzerland
Infliximab	Chile
Remicade	Argentina, Australia, Austria, Belgium, Canada, Chile, Colombia, Denmark, Ecuador, Finland, France, Germany, Great Britain, Greece, Iceland, Iran, Ireland, Italy, Japan, Luxembourg, Malaysia, Mexico, Netherlands, New Zealand, Norway, Peru, Poland, Portugal, Romania, Saudi Arabia, Spain, Sweden, Switzerland, Tunisia, Turkey, United Arab Emirates, United States of America, Venezuela
Remsima	Argentina, Belgium, Canada, Chile, Ecuador, France, Germany, Great Britain, Iceland, Italy, Norway, Peru, Romania, Spain, Switzerland, Turkey
Zessli	Belgium, Germany, Great Britain

References

injection

References : Infliximab

	Type	Publication
754	Manufacturer	Infliximab (Remicade®) – Summary of Product Characteristics Merck Sharp & Dohme 2019
2296	Manufacturer	Témocilline (Negaban®) - Résumé des caractéristiques du produit Eumedica 2017
3137	Journal	Beer PM, Wong SJ, Schartman JP, Kulas KE, Hartman CL, Giganti M, Falk NS. Infliximab stability after reconstitution, dilution, and storage under refrigeration. Retina 2010 ; 30, 1: 81-84.
3317	Poster	Guirao S, Paul M, Jaccoulet E, Morand K, Astier A. Stabilité de l'infliximab en solutions diluées. APHIF Congress 2009
3333	Journal	Ikeda R, Vermeulen L.C, Lau E, Jiang Z, Saha S, Reichelderfer M, Kolesar J.M. Stability of infliximab in polyvinyl chloride bags. Am J Health-Syst Pharm 2012 ; 69:1509-1512.
3825	Journal	Young B.L, Ali Khan M, Chapman T.J, Parry R,. Connolly M.A, Watts A.G. Evaluation of the physicochemical and functional stability of diluted REMSIMA(R) upon extended storage—A study compliant with NHS (UK) guidance. J Pharm Pract and Res 2015 ; 496: 421-431.
3924	Journal	Vieillard V, Astier A, Sauzay C, Paul M. One-month stability study of a biosimilar of infliximab (Remsima®) after dilution and storage at 4 C and 25 C. Ann Pharm Fr 2016 ; 75, 1 : 17-29.
4003	Journal	Kim J, Chung J, Park S, Jung S, Kang D. Evaluation of the physicochemical and biological stability of reconstituted and diluted SB2 (infliximab). EJHP 2017 ; 25, 3: 157-164.
4049	Journal	Tokhadze N, Chennell P, Le Basle Y, Sautou V. Stability of infliximab solutions in different temperature and dilution conditions. J Pharm Biomed Anal 2018 ; 150 : 386-395
4279	Journal	Hermosilla J, Sanchez-Martin R, Pérez-Robles R, Salmeron-Garcia A, Casares S, Cabeza J, Cuadros-Rodriguez L, Navas N. Comparative Stability Studies of Different Infliximab and Biosimilar CT-P13 Clinical Solutions by Combined Use of Physicochemical Analytical Techniques and Enzyme-Linked Immunosorbent Assay (ELISA). Bio Drugs 2019 ; 33: 193–205.
4292	Journal	Vimpolsek M, Gottar-Guillier M, Rossy E. Assessing the Extended In-Use Stability of the Infliximab Biosimilar PF-06438179/GP1111 Following Preparation for Intravenous Infusion. Drugs R D 2019 19: 127–140.

Mentions Légales